MURRAY - 04 Apr 2023 Form 4 Insider Report for Jounce Therapeutics, Inc.

Role: Director
Signature: /s/ Caroline G. Gammill, by power of attorney
Issuer symbol: N/A
Transactions as of: 04 Apr 2023
Net transactions value: -$72,572
Form type: 4
Filing time: 06 Apr 2023, 16:37:50 UTC
Previous filing: 11 Jan 2023
Next filing: 04 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JNCE	Common Stock	Sale	$72,572	-39,228	-17%	$1.85	188,779	04 Apr 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The automatic sale instructions for the sell-to-cover were intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended, and to be interpreted to comply with the requirements of Rule 10b5-1(c), and these instructions were given on September 17, 2019.

Content

Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The automatic sale instructions for the sell-to-cover were intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended, and to be interpreted to comply with the requirements of Rule 10b5-1(c), and these instructions were given on September 17, 2019.